Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.

##STR00001##

The present disclosure relates to a cocrystal of telmisartan and hydrochlorothiazide, a preparation method and use thereof. In the cocrystal, the molar ratio of telmisartan and hydrochlorothiazide is 1:1. The cocrystal of telmisartan and hydrochlorothiazide was characterized by X-ray powder diffraction (XRPD), proton nuclear magnetic resonance spectra (1H-NMR), thermal gravimetric analysis (TG), scanning differential calorimetry (DSC) and infrared (IR) spectra, and it was found that the maximum plasma concentration of the cocrystal in SD rats was higher than that of any one of hydrochlorothiazide and telmisartan itself. The cocrystal of telmisartan and hydrochlorothiazide has a simple preparation method and good physical and chemical properties.

Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2. ##STR00001##